News | October 06, 2024
Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Developed in consultation with clinicians and patients for an enhanced user experience
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Subscribe To Our Newsletter & Stay Updated
